



NEXTGEN

IS ALWAYS

SMARTER



BETAMAX MINI DISC
386 CASSETTE
35mm FILM
FLOPPY DISK
VHS
CATHODE RAY
ANALOG TUBE
8 TRACK

LCD
MOBILE FLASH DRIVE
MP3 DIGITAL
SOCIAL MEDIA
CELL PHONE
FLATSCREEN
TABLET

ESOGRESS

Enteric Coated Tablets of Esomeprazole 40 mg

ESOGRESS-D

Esomeprazole(Enteric Coated) 40 mg with
Domperidone 30 mg Sustained Release Capsules

ESOGRESS-L

Esomeprazole(Enteric Coated) 40 mg with
Levosulpiride Sustained Release 75 mg Capsules

ESOGRESS

Enteric Coated Tablets of
Esomeprazole 40 mg

ESOGRESS-D


Esomeprazole(Enteric Coated) 40 mg with
Domperidone 30 mg Sustained Release Capsules

ESOGRESS-L

Esomeprazole(Enteric Coated) 40 mg with
Levosulpiride Sustained Release 75 mg Capsules

Esomeprazole in Esogress offers :

- More effective intragastric acid control.¹
- No major safety concern arose in long term therapy.²
- As adjuvant therapy in glycemc patient.³
- Effective in maintaining intragastric pH at 4.0 compared to other PPI.⁴



Source:- Int J Basic Clin Pharmacol. 2014 Jun;3(3):460-464

Conclusion : Esomeprazole is more effective than pantoprazole for rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis.

In Diabetes :

The study was conducted to evaluate the effect of chronic PPIs treatment on glycemc control in patients affected by type 2 diabetes.

Sr No	PATIENT GROUP	PARAMETERS	
		FPG (mg/dl)	HBA1c(mmol/mol)
1	Control Group	147	7.4
2	PPI Treated Group	127	7.1

Source:- Acta Diabetol (2015) 52:873-880

Conclusion : PPIs treatment is associated with greater glycemc control in patients with type 2 diabetes, particularly in those on insulin.

ESOGRESS

Enteric Coated Tablets of
Esomeprazole 40 mg

ESOGRESS-D

Esomeprazole(Enteric Coated) 40 mg with
Domperidone 30 mg Sustained Release Capsules

ESOGRESS-L

Esomeprazole(Enteric Coated) 40 mg with
Levosulpiride Sustained Release 75 mg Capsules

Domperidone in Esogress-D offers :

- Domperidone is a unique gastro kinetic and antiemetic drug.⁶
- In the management of diabetic gastropathy, domperidone's antiemetic activity distinguishes it from cisapride.⁶
- It does not cross the blood-brain barrier and therefore has fewer CNS side effects.⁷
- Domperidone has been shown to reduce GI symptoms and hospitalizations from gastroparesis, accelerate gastric emptying, and enhance quality of life.⁸

Levosulpiride in Esogress-L :

- Increases glycemic control in IDDM subjects, manages Gastroparesis.⁹
- Useful in functional dyspepsia.¹⁰
- Levosulpiride have more efficacy in management of dyspeptic symptoms in comparison to anti-secretory agents (cimetidine, ranitidine) and prokinetic agents (metaclopramide, domperidone).¹¹
- Levosulpiride is as effective as cisapride in management of dyspepsia, having better tolerability, and relatively milder adverse events.¹¹
- Levosulpiride quicken gastric and gall bladder emptying.¹¹
- Unlike cisapride, levosulpiride is devoid of serious cardiovascular adverse effect.¹¹

Effectiveness of Levosulpiride :

Sr No	PATIENT POOL	15 DAYS OF TREATMENT	30 DAYS OF TREATMENT
1	342 patients (279 patients of functional dyspepsia & 63 of NERD)	Symptoms ↓sed by 50 %	Almost all symptoms were disappeared

Source:- R Lozano et al; Therapeutics and Clinical Risk Management 2007;3(1) 149–155

References :

1. European Journal of Clinical Pharmacology;(60)(8):pp 531-539:2004.
2. Aliment Pharmacol Ther;2015.
3. Diabetes Research and Clinical Practice; 90: e73-e74: 2010.
4. Therapeutics and Clinical Risk Management 2007;3(4) 653–663.
5. Clin Pharmacokinet. 2001;40(6):411-26.
6. Barone JA et al; Domperidone: a peripherally acting dopamine2-receptor antagonist.
7. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230–4.
8. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998;20:438–53.
9. Diabetes Care;21:51-8.
10. Gastroenterol Hepatol;33(8)2010.
11. Ratnani JJ et al; Role of Levosulpiride in the Management of Functional Dyspepsia. J Fam Med. 2015;2(4): 1034.
12. R Lozano et al; Therapeutics and Clinical Risk Management 2007;3(1) 149–155.

ESOGRESS

Enteric Coated Tablets of
Esomeprazole 40 mg

ESOGRESS-D

Esomeprazole(Enteric Coated) 40 mg with
Domperidone 30 mg Sustained Release Capsules

ESOGRESS-L

Esomeprazole(Enteric Coated) 40 mg with
Levosulpiride Sustained Release 75 mg Capsules

Indications :

- GERD
- NAB (Nocturnal Acid Breakthrough)
- Diabetic Gastroparesis
- Functional Dyspepsia
- Gastritis

Mechanism of action :

Esomeprazole is the S-enantiomer of omeprazole, specifically act on proton pump inhibitor, suppressing gastric acid secretion by specific inhibition of the H⁺/K⁺-ATPase in the gastric parietal cell and blocking the final step in acid production, resulting in reduced gastric acidity.

Domperidone has strong affinities for the D2 and D3 dopamine receptors, found in the chemoreceptor trigger zone, located just outside the blood brain barrier. It facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure.

Levosulpiride is a sulpiride isomer that exerts its prokinetic action through a dual mechanism, as a D2 dopamine receptor antagonist and as a serotonin 5HT₄ receptor agonist.

Storage :

Store at a temperature not exceeding 30°C.
Keep at cool and dry place.

Presentation :

Esogress :

Enteric Coated Tablets of Esomeprazole 40 mg.

Esogress-D :




Esomeprazole(EC) 40 mg with Domeperidone Sustained Release 30 mg Capsules.

Esogress-L :

Esomeprazole(EC) 40 mg with Levosulpiride Sustained Release 75 mg Capsules.

La Renon Healthcare Pvt. Ltd.

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998 (30 lines) | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

 I am: _____
 Call me on: _____
 Mail me at: _____

©2018 All rights reserved, La Renon Healthcare Pvt. Ltd.